{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"111"}]}],"title":"Any TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"41"}]}],"title":"Any treatment- emergent SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"description":"To determine the safety and tolerability of Sunvozertinib: Number of Participants With AEs, Number of Participants With SAEs. Using investigator reported AEs according to CTCAE and SAE criteria.","groups":[{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized to receive sunvozertinib 200 mg once daily continuously.","id":"OG000","title":"Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized to receive sunvozertinib 300 mg once daily continuously.","id":"OG001","title":"Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg"}],"paramType":"NUMBER","populationDescription":"all patients had at least one dose of DZD9008","reportingStatus":"POSTED","timeFrame":"Through the study completion, an average of around 1 year for part B","title":"Part B: AEs/SAEs","type":"SECONDARY","unitOfMeasure":"participants"}